EL7.AI
StocksMediumUpdated×3•Originally published 6 August 2026•Updated 6 August 2026•
1 min read

Moderna Wins FDA Approval for mFLUSIVA Flu Vaccine for Adults 50+

Key Facts

1The U.S. FDA approved Moderna's mFLUSIVA (mRNA-1010) vaccine for adults aged 50 and older.

In a move that strengthens the company's position in the mRNA vaccine market, Moderna announced that the U.S. Food and Drug Administration (FDA) has approved its seasonal influenza vaccine, mFLUSIVA. This approval is specifically for adults aged 50 and older, expanding the preventative options available for this demographic. The decision follows a unanimous recommendation from the FDA's advisory committee, marking the fourth FDA-approved product for the company.

According to reports, this regulatory milestone represents a significant development for Moderna, establishing a new revenue stream within the influenza vaccine sector. The approval aligns with the previously established PDUFA date of August 5, meeting market expectations for the timing of the decision. This development underscores the company's progress in diversifying its approved product portfolio beyond its initial COVID-19 offerings.

Looking ahead at the economic calendar, there are no major upcoming biotech-specific catalysts scheduled for the next seven days; however, investors will be watching for how this new product launch impacts the company's long-term financial guidance.

Latest Updates · 2

  1. Notable·

    Update: The mFLUSIVA vaccine is expected to be available for the 2026-2027 influenza season. The FDA granted traditional approval for adults aged 50-64, while those 65 and older received accelerated approval. This milestone follows the resolution of a regulatory hurdle from February, further solidifying the company's commercial outlook.

  2. Notable·

    Update: This approval marks a historic shift in the healthcare sector, as mFLUSIVA becomes the first-ever mRNA-based seasonal influenza vaccine to receive official authorization. This milestone is expected to pave the way for a new generation of vaccines that offer greater flexibility in addressing seasonal viral mutations.